2024 Partners
Bionaut
Lead Partner
Revolutionizing drug delivery to the brain. Bionaut is a global biotechnology and drug delivery company dedicated to pioneering innovative solutions for brain-targeted therapies. Our cutting-edge precision drug delivery platform enables the accurate, safe, and effective administration of treatments to challenging brain regions for a diverse range of therapeutics. Backed by robust pre-clinical safety data and poised for upcoming 2024 clinical trials, Bionaut is seeking partnerships with forward-thinking pharmaceutical industry pioneers to join our mission. Together, we can unravel the complexities of localized brain conditions and transform neurological care. Join us at the conference and learn more about our mission.
Aptar Pharma
Programme Partner
Aptar Pharma is an expert in nasal drug delivery, offering advanced intranasal systems and drug delivery services from design and manufacture, formulation development and clinical product manufacturing to post launch support. Our global network of GMP manufacturing sites help us accelerate and derisk drug product development, and our investments in R&D and innovation allow us to offer proven nasal drug delivery solutions to help improve patient outcomes across the globe. Aptar Pharma is part of AptarGroup, Inc.
Renishaw
Hosting Partner
Renishaw Neuro Solutions enables direct-to-target delivery for a broad range of applications. Using the neuroinfuse™ drug delivery system, predictable and translatable therapy infusions in R&D and clinical trials can become a reality.
Our Lab2Clinic™ service supports pharma through the R&D journey, translating into clinical trials and scaled-up commercialisation. We have a wide geographical reach, and we focus on promoting long-term partnerships.
All this is underpinned by our FDA-cleared, CE-marked stereotactic products borne out of a +45-year precision engineering heritage.
Neurochase
Hosting Partner
Neurochase is delivering transformative therapy solutions for companies tackling life-limiting and life-threatening neurological conditions, including MND, Parkinson’s and Huntington’s Disease.
Established in 2020 by Founder and Chief Scientific Officer, Steven Gill, UK-based Neurochase is a world leading authority in CNS drug delivery.
The company develops state-of-the-art, bespoke, and globally scalable solutions for the pharmaceutical and biotech industries to enable the delivery of gene therapy and other treatments safely and effectively.
Realeve
Innovation Partner
Realeve is a medical device company dedicated to developing innovative solutions for autonomic disorders with an initial focus on cluster headaches treartment, but with the ultimate goal of pioneering work in Blood Brain Barrier permeability. This MRI-compatible neurostimulator device (FDA breakthrough) offers ondemand stimulation of the sphenopalatine ganglion (SPG), a key nerve structure involved in autonomic disorders by regulating blood brain barrier flow/permeability. The Pulsante System has been successfully implanted in over 700 patients in the US/Europe, with promising results, including a randomized controlled trial published in The Lancet.
